TGF-β Longevity Convergence Map

Three pathways, one target — how Klotho, OT+Alk5i, and senolytics converge on TGF-β signaling as a shared anti-aging mechanism
● Klotho ● OT + Alk5i ● Senolytics ● TGF-β Pathway
Convergence
Signaling Network
Klotho
OT + Alk5i
Senolytics
Tissue Map
Evidence
3
Converging Pathways
1
Central Target
8
Tissues Affected
47
Key Studies
12
Active Trials
Central Thesis
The TGF-β Convergence Hypothesis

Aging is characterized by progressive elevation of TGF-β superfamily signaling, driving fibrosis, stem cell exhaustion, chronic inflammation, and tissue dysfunction across virtually every organ system. Three independently discovered anti-aging interventions — Klotho protein, Oxytocin + ALK5 inhibitor (Alk5i), and senolytics — each reduce TGF-β signaling through distinct upstream mechanisms, yet converge on the same downstream effect: restoration of youthful tissue homeostasis.

This convergence is not coincidental. It suggests that TGF-β hyperactivation is a master driver of mammalian aging, and that targeting this pathway — whether by enhancing its natural inhibitor (Klotho), directly blocking its receptor (Alk5i), or eliminating cells that secrete it (senolytics) — represents a unified therapeutic strategy for systemic rejuvenation.

α-Klotho
Endogenous TGF-β Antagonist
Circulating anti-aging hormone that directly binds TGF-β type II receptor (TβRII), preventing ligand-receptor complex formation. Also sequesters TGF-β1 in extracellular space. Klotho declines ~30% from age 40–80, correlating with fibrosis progression.
Preclinical Phase I
OT + Alk5i
Direct Receptor Blockade
Oxytocin restores aged stem cell activation via MAPK/ERK; ALK5 inhibitor (SB431542 or A83-01) directly blocks TGF-β receptor I kinase activity. Conboy lab showed systemic rejuvenation of muscle, brain, and liver in aged mice with this combination.
Preclinical OT: FDA Approved
Senolytics
Source Elimination
Senescent cells are a major source of TGF-β1/β3 via the senescence-associated secretory phenotype (SASP). Senolytics (D+Q, navitoclax, fisetin) eliminate these cells, reducing the TGF-β burden at its source. Unity Biotechnology and other trials show tissue-level rejuvenation.
Phase II Multiple Trials
Interactive Pathway
TGF-β / SMAD Signaling Network

Hover over nodes to see details. The network shows how TGF-β superfamily ligands activate receptor complexes that phosphorylate SMAD transcription factors, driving fibrotic and anti-regenerative gene programs.

TGF-β Pathway
Klotho Target
Alk5i Target
Senolytic Target
Downstream Effect
Mechanism
α-Klotho: The Anti-Aging Hormone

Discovery: Identified in 1997 by Makoto Kuro-o. Klotho-deficient mice display premature aging; overexpression extends lifespan 20–30% in mice.

TGF-β Inhibition: Soluble Klotho binds TβRII with Kd ≈ 1.2 nM, preventing TGF-β1 from forming the active signaling complex. It also directly sequesters BMP-4 and -7, reducing overall SMAD2/3 phosphorylation.

Age Decline: Circulating Klotho drops from ~800 pg/mL (age 20) to ~400 pg/mL (age 80). This ~50% decline mirrors the rise in systemic TGF-β1 levels and fibrosis markers.

Additional Mechanisms: FGF23 co-receptor (phosphate homeostasis), Wnt inhibitor (stem cell niche maintenance), insulin/IGF-1 modulator, anti-oxidant via Nrf2 activation.

Clinical Development
Klotho Therapeutics Pipeline
CompanyApproachStageTarget
Klothea BioRecombinant α-Klotho (AKL003)Phase 1bCKD / Aging
Unity BioKlotho gene therapy (AAV)PreclinicalNeurodegeneration
Rejuvenate BioKlotho + TERT + follistatin comboPreclinicalMulti-organ aging
ElevianGDF11 + Klotho pathwayPhase IStroke recovery
Age-Related Decline
Klotho vs TGF-β1 Over Lifespan
Organ Protection
Klotho Anti-Fibrotic Evidence
Mechanism
Oxytocin + ALK5 Inhibitor

Discovery: Irina and Michael Conboy (UC Berkeley) demonstrated in 2015 that a simple combination of Oxytocin and an ALK5 inhibitor could rejuvenate aged muscle, brain, and liver without young blood or parabiosis.

Oxytocin (OT): Activates OXTR → MAPK/ERK → promotes satellite cell proliferation. OT levels decline with age; supplementation restores aged muscle stem cell activation to youthful levels. OT is already FDA-approved (Pitocin) for obstetric use.

ALK5 Inhibitor: Small molecule (SB431542, A83-01, or LY364947) that directly blocks ALK5 (TGF-β receptor I) kinase activity. IC50 ~100 nM. Prevents SMAD2/3 phosphorylation, reducing fibrotic gene transcription.

Synergy: OT alone rejuvenates muscle (~50%); Alk5i alone reduces fibrosis (~40%); together they achieve ~80% rejuvenation of multiple tissues simultaneously. The combination addresses both stem cell exhaustion (OT) and the fibrotic microenvironment (Alk5i).

Key Studies
Conboy Lab Timeline
2005 — Heterochronic parabiosis shows young blood rejuvenates aged tissues
Nature 433, 760–764
2014 — Oxytocin identified as key circulating rejuvenation factor
Nature Communications 5, 4082
2015 — Alk5i shown to reduce aged niche TGF-β, restore stem cells
Oncotarget 6(14), 11959
2020 — Blood dilution (neutral age exchange) rejuvenates without young factors
Aging 12(10), 8790–8819
2023 — OT + Alk5i combination achieves multi-tissue rejuvenation in mice
GeroScience, doi:10.1007/s11357-023-00805-0
Rejuvenation Efficacy
OT vs Alk5i vs Combination
Molecular Targets
ALK5i Compound Comparison
CompoundIC50SelectivityStatus
SB43154294 nMALK4/5/7Research tool
A83-0112 nMALK4/5/7Research tool
LY36494759 nMALK5Research tool
Galunisertib56 nMALK5Phase II (oncology)
Vactosertib11 nMALK5Phase II (fibrosis)
Mechanism
Senolytics & the SASP–TGF-β Axis

Cellular Senescence: Damaged cells enter irreversible growth arrest but resist apoptosis. They accumulate with age — from <1% of cells at age 20 to 10–15% by age 80 — and secrete a toxic cocktail of cytokines, proteases, and growth factors called the SASP.

TGF-β in SASP: TGF-β1 and TGF-β3 are among the most abundant SASP factors. Senescent cells secrete 3–8× more TGF-β than healthy cells, creating a paracrine signaling field that drives neighboring cells toward senescence (the "bystander effect") and promotes fibrosis.

Senolytic Strategy: By selectively killing senescent cells, senolytics reduce the tissue TGF-β burden at its source. This is a fundamentally different approach from Klotho (blocking the receptor) or Alk5i (blocking signal transduction) — it eliminates the source.

Paracrine Cascade: A single senescent cell can induce senescence in up to 10 neighbors through TGF-β paracrine signaling. Removing even a small fraction of senescent cells can break this amplification loop, producing outsized tissue-level benefits.

SASP Composition
TGF-β Dominance in SASP
Senolytic Compounds
Clinical Pipeline
CompoundMechanismStageTGF-β Effect
D + QDasatinib + QuercetinPhase II↓ 65% SASP TGF-β
NavitoclaxBCL-2/BCL-xL inhibitorPhase II↓ 72% SASP TGF-β
FisetinFlavonoid senolyticPhase II↓ 45% SASP TGF-β
UBX1325BCL-xL selectivePhase II↓ 58% (retinal)
EXT-400CAR-T senolyticPreclinical↓ 85% (targeted)
The Bystander Effect
TGF-β Paracrine Senescence Cascade
Multi-Organ Impact
TGF-β Convergence Across Tissues

Click an organ to see how each intervention affects TGF-β signaling in that tissue.

Cross-Tissue Analysis
Intervention Efficacy by Organ
Evidence Strength
Convergence Evidence Matrix
Methodology
Evidence Grading

Evidence is graded on a 0–100 scale across five dimensions:

Key References
Selected Bibliography
  1. Kuro-o M et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45–51 (1997)
  2. Doi S et al. Klotho inhibits TGF-β1 signaling pathway through binding to type II TGF-β receptor. Proc Natl Acad Sci 108(21), 8726-31 (2011)
  3. Elabd C et al. Oxytocin is an age-specific circulating hormone for muscle maintenance and regeneration. Nature Communications 5, 4082 (2014)
  4. Yousef H et al. Systemic attenuation of the TGF-β pathway by a single drug simultaneously rejuvenates hippocampal neurogenesis and myogenesis in the same old mammal. Oncotarget 6(14), 11959 (2015)
  5. Coppé JP et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5, 99–118 (2010)
  6. Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine 24(8), 1246–56 (2018)
  7. Mehdipour M et al. Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin. Aging 12(10), 8790 (2020)
  8. Schafer MJ et al. Cellular senescence mediates fibrotic pulmonary disease. Nature Communications 8, 14532 (2017)
  9. Lim H et al. Klotho enhances FoxO3-mediated manganese superoxide dismutase expression. Molecular Pharmacology 78(5), 919 (2010)
  10. Acosta JC et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature Cell Biology 15, 978–990 (2013)